Search research articles
Contact Us
Filters
Showing results (61-70 of 160) with videos related to
Page
of 16
Sort By:
Dalton Transactions (Cambridge, England : 2003)
|
October 21, 2017
Mechanistic exploration of the copper(i) phosphide synthesis in phosphonium-based and phosphorus-free ionic liquids
Mai Lê Anh, Alexander Wolff, Martin Kaiser, et al.
Anti-Cancer Drugs
|
August 24, 2006
Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma
Jan Eucker, Jan Sterz, Holger Krebbel, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|
June 4, 2020
The Weak 3D Topological Insulator Bi<sub>12</sub> Rh<sub>3</sub> Sn<sub>3</sub> I<sub>9</sub>
Mai Lê Anh, Martin Kaiser, Madhav Prasad Ghimire, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
August 6, 2011
Gut-derived factors promote neurogenesis of CNS-neural stem cells and nudge their differentiation to an enteric-like neuronal phenotype
Subhash Kulkarni, Bende Zou, Jesse Hanson, et al.
The Journal of Organic Chemistry
|
October 12, 2007
Preparation of novel unsymmetrical bisindoles under solvent-free conditions: synthesis, crystal structures, and mechanistic aspects
Hanns Martin Kaiser, Ivo Zenz, Wei Fun Lo, et al.
Nanoscale
|
June 25, 2015
Quenching of the upconversion luminescence of NaYF₄:Yb³⁺,Er³⁺ and NaYF₄:Yb³⁺,Tm³⁺ nanophosphors by water: the role of the sensitizer Yb³⁺ in non-radiative relaxation
Riikka Arppe, Iko Hyppänen, Niina Perälä, et al.
BMJ Open
|
March 25, 2021
MUK<i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia
Sarah Brown, Debbie Sherratt, Samantha Hinsley, et al.
European Journal of Haematology
|
April 9, 2010
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma
Jan Sterz, Christian Jakob, Ulrike Kuckelkorn, et al.
Blood Cancer Journal
|
February 24, 2019
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Heinz Ludwig, Philippe Moreau, Meletios A Dimopoulos, et al.
Leukemia Research
|
December 16, 2010
Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia
Gero Hütter, Martin Kaiser, Martin Neumann, et al.
Page
of 16
Search research articles
Search
Showing results (61-70 of 160) with videos related to
Sort By:
Page
of 16
Dalton Transactions (Cambridge, England : 2003)
|
October 21, 2017
Mechanistic exploration of the copper(i) phosphide synthesis in phosphonium-based and phosphorus-free ionic liquids
Mai Lê Anh, Alexander Wolff, Martin Kaiser, et al.
Anti-Cancer Drugs
|
August 24, 2006
Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma
Jan Eucker, Jan Sterz, Holger Krebbel, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|
June 4, 2020
The Weak 3D Topological Insulator Bi<sub>12</sub> Rh<sub>3</sub> Sn<sub>3</sub> I<sub>9</sub>
Mai Lê Anh, Martin Kaiser, Madhav Prasad Ghimire, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
August 6, 2011
Gut-derived factors promote neurogenesis of CNS-neural stem cells and nudge their differentiation to an enteric-like neuronal phenotype
Subhash Kulkarni, Bende Zou, Jesse Hanson, et al.
The Journal of Organic Chemistry
|
October 12, 2007
Preparation of novel unsymmetrical bisindoles under solvent-free conditions: synthesis, crystal structures, and mechanistic aspects
Hanns Martin Kaiser, Ivo Zenz, Wei Fun Lo, et al.
Nanoscale
|
June 25, 2015
Quenching of the upconversion luminescence of NaYF₄:Yb³⁺,Er³⁺ and NaYF₄:Yb³⁺,Tm³⁺ nanophosphors by water: the role of the sensitizer Yb³⁺ in non-radiative relaxation
Riikka Arppe, Iko Hyppänen, Niina Perälä, et al.
BMJ Open
|
March 25, 2021
MUK<i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia
Sarah Brown, Debbie Sherratt, Samantha Hinsley, et al.
European Journal of Haematology
|
April 9, 2010
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma
Jan Sterz, Christian Jakob, Ulrike Kuckelkorn, et al.
Blood Cancer Journal
|
February 24, 2019
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
Heinz Ludwig, Philippe Moreau, Meletios A Dimopoulos, et al.
Leukemia Research
|
December 16, 2010
Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia
Gero Hütter, Martin Kaiser, Martin Neumann, et al.
Page
of 16